


AMENDMENTS TO THE CLAIMS

The following Listing of the Claims replaces all prior claims in the application.



1. (Original): β -carboline derived guanidine alkaloid, tiruchenduramine of the Formula 1



1



isolated from an ascidian *Synoicum macroglossum* and its derivatives thereof.

2. (Original): A compound as claimed in claim 1 selected from the following:



1. $R_1=R_2=R_3=H$, $n=2$
2. $R_1=R_2=R_3=H$, $n=3$
3. $R_1=R_2=R_3=H$, $n=4$
4. $R_1=R_2=R_3=H$, $n=5$
5. $R_1=R_2=R_3=H$, $n=6$

6. $R_1=R_2=R_3=H$, $n=2$
7. $R_1=R_2=R_3=H$, $n=3$
8. $R_1=R_2=R_3=H$, $n=4$
9. $R_1=R_2=R_3=H$, $n=5$
10. $R_1=R_2=R_3=H$, $n=6$




11. R₁ = Piperzine, R₂=R₃=H, n=2
12. R₁ = Piperzine, R₂=R₃=H, n=3
13. R₁ = Piperzine, R₂=R₃=H, n=4
14. R₁ = Piperzine, R₂=R₃=H, n=5
15. R₁ = Piperzine, R₂=R₃=H, n=6

16. R₁ = Piperzine, R₂ = R₃ = H, n = 2
17. R₁ = Piperzine, R₂ = R₃ = H, n = 3
18. R₁ = Piperzine, R₂ = R₃ = H, n = 4
19. R₁ = Piperzine, R₂ = R₃ = H, n = 5
20. R₁ = Piperzine, R₂ = R₃ = H, n = 6

3. (Original): A process for the preparation of β -carboline derived guanidine alkaloid tiruchenduramine of Formula 1

Second Preliminary Amendment



1

a pharmaceutically acceptable carrier, vehicle or excipient.

12. (Previously Presented): A pharmaceutical composition comprising as an active ingredient a compound as claimed in claim 2 and a pharmaceutically acceptable carrier, vehicle or excipient.

13 (Previously Presented): A composition claimed in claim 11 wherein said composition is used for the treatment of diabetic disorders and wherein said active ingredient is present in an amount of about 78.8 μ g.

14. (Previously Presented): A composition as claimed in claim 13 wherein the unit dosage of said composition is from about 15 mg to about 480 mg.

15 (Previously Presented): A pharmaceutical composition comprising a first therapeutic agent consisting of a β -carboline derivative guanidine alkaloid, tiruchenduramine selected from the group consisting of compounds 1 through 20 and a second therapeutic agent different from said first therapeutic agent.

16. (Previously Presented): A composition as claimed in claim 15 wherein said second therapeutic agent is selected from alkylating agents, antimetabolites, vinca alkaloids, antibiotics, cytokines, growth factors and non-steroidal anti-inflammatory drugs.

17. (Currently Amended): A method of treating diabetic disorders in a mammal in need thereof wherein the method comprises administration of a β -carboline derivative guanidine

alkaloid, tiruchenduramine selected from the group consisting of compounds 1 through 20 ~~in the treatment of diabetic disorders.~~

18. (Previously Presented): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a β -carboline derivative guanidine alkaloid, tiruchenduramine selected from the group consisting of compounds 1 through 20.

19. (Previously Presented): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 11.

20. (Previously Presented): A composition as claimed in claim 13 wherein the unit dosage of said composition is from about 24 mg to about 280 mg.

21. (Previously Presented): A composition claimed in claim 12 wherein said composition is used for the treatment of diabetic disorders and wherein said active ingredient is present in an amount of about 78.8 μ g.

22. (New): A composition as claimed in claim 21 wherein the unit dosage of said composition is from about 24 mg to about 280 mg.

23. (New): A composition as claimed in claim 21 wherein the unit dosage of said composition is from about 15 mg to about 480 mg.

24. (New): A process as claimed in claim 4 wherein said extraction comprises extraction in the presence of methanol followed by a dichloromethane:methanol extraction and the extract so obtained is subject to purification.

25. (New): A process as claimed in claim 24 wherein said ascidian comprises freeze dried *Synoicum macroglossum*.

26. (New): A process as claimed in claim 25 wherein said dichloromethane and methanol are used in a ratio of 1:1.

27. (New): A process as claimed in claim 26 wherein after extraction with dichloromethane and methanol, the extract so obtained is partitioned between water and ethyl acetate.

28. (New): A process as claimed in claim 27 wherein said water extract is lyophilized and the residue is triturated with methanol.

29. (New): A process as claimed in claim 6 wherein said purification comprises a Sephadex LH-20 column chromatography.

30. (New): A process as claimed in claim 7 wherein said purification comprises a Sephadex LH-20 column chromatography.

31. (New): A process as claimed in claim 8 wherein said purification comprises a Sephadex LH-20 column chromatography.

32. (New): A process as claimed in claim 9 wherein said purification comprises a Sephadex LH-20 column chromatography.

33. (New): A process as claimed in claim 24 wherein said purification comprises a Sephadex LH-20 column chromatography.

34. (New): A process as claimed in claim 25 wherein said purification comprises a Sephadex LH-20 column chromatography.

35. (New): A process as claimed in claim 26 wherein said purification comprises a Sephadex LH-20 column chromatography.

36. (New): A process as claimed in claim 27 wherein said purification comprises a Sephadex LH-20 column chromatography.

37. (New): A process as claimed in claim 28 wherein said purification comprises a Sephadex LH-20 column chromatography.

38. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 12.
39. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 13.
40. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 14.
41. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 15.
42. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 16.
43. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 20.
44. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 21.
45. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 22.
46. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 23.
47. (New): A composition of claim 16, wherein the non-steroidal anti-inflammatory is aspirin.